Serum Selenium and Subsequent Risk of Prostate Cancer

Abraham M. Y. Nomura,1 James Lee, Grant N. Stemmermann, and Gerald F. Combs, Jr.
Japan-Hawaii Cancer Study, Kuakini Medical Center, Honolulu, Hawaii 96817 [A. M. Y. N., J. L.]; Department of Pathology, University of Cincinnati Medical Center, Cincinnati, Ohio 45267 [G. N. S.]; Division of Nutritional Sciences, Cornell University, Ithaca, New York 14853 [G. F. C.]

Abstract

It is suspected that selenium is protective against prostate cancer. To test this hypothesis, we conducted a nested case-control study in a cohort of 9345 Japanese-American men examined between 1971 and 1977. At the time of examination, a blood specimen was obtained, and the serum was frozen. After a surveillance period of more than 20 years, 249 tissue-confirmed incident cases of prostate cancer were identified. Their stored sera and those of 249 matched controls were measured for selenium levels. Odds ratios for prostate cancer, based on quartiles of serum selenium levels, were determined using the General Estimating Equations approach. The multivariate odds ratio for the highest quartile was 0.5 (95% confidence interval, 0.3–0.9) with a two-sided P for trend of 0.02. The inverse association was more notable for cases with advanced disease and for cases diagnosed 5–15 years after phlebotomy. However, the association was mainly present in current or past cigarette smokers rather than nonsmokers, which leads to caution in the interpretation of the results.

Introduction

Selenium is a nutritionally essential trace element with anticarcinogenic properties. It is a constituent of several enzymes, including some with antioxidant functions: the glutathione peroxidases and thioredoxin reductase, which remove hydroperoxides formed during oxidative metabolism, thereby reducing the potential for oxidative damage to DNA, proteins, and polyunsaturated membrane phospholipids (1). Supranutritional doses of selenium compounds have also been shown to inhibit tumorigenesis induced by chemical or viral agents or by transplantation in a large number of studies using animal models (2). Human epidemiological investigations have been less conclusive but have generally supported the plausibility of antimitogenic effects of selenium for at least some cancers (2).

There have been only a few controlled prevention trials to test the hypothesis that selenium can be protective against cancer in humans. Studies conducted in China suggested that selenium supplementation reduced liver cancer incidence (3) and, together with β-carotene and vitamin E, reduced stomach cancer mortality (4). In the United States, a randomized, double-blind, cancer prevention trial was done in which 1312 patients with a history of basal cell or squamous cell carcinomas of the skin were given either 200 μg of selenium or a placebo. The investigators reported the lack of a protective effect of selenium against recurrent skin cancer (5). However, the incidence of carcinomas, especially carcinomas of the lung, colorectum, and prostate, was lower in the treatment group. A subsequent report highlighted the observation that there were 35 incident cases of prostate carcinoma in the placebo group, but only 13 prostate carcinoma cases in the selenium supplementation group (6).

A recent study strengthened the case that selenium may be protective against prostate cancer (7). Toenail clippings were collected from 33,737 men in the Health Professional Follow-Up Study. Toenails are regarded as being useful in reflecting the average intake of selenium over many months (8). After a 7-year observation period, the researchers found that high selenium levels in toenails were associated with a reduced risk of advanced prostate cancer in 181 patients. In this study, the controls were matched to the cases on smoking status because past investigators have reported that cigarette smoking is a predictor of lowered selenium levels (9–11).

A single serum measurement of selenium also correlates well with selenium intake (8). Therefore, several prospective studies have investigated the relation of serum selenium levels to the subsequent incidence of cancers at different sites (12–19). Three of the studies included cases of prostate cancer that, when combined, totaled just 75 cases in all (17–19). The largest study reported no association (17), whereas the two smaller studies showed a nonsignificant inverse association of serum selenium with prostate cancer (18–19).

The purpose of the present study was to further investigate the relation of serum selenium levels to prostate cancer risk. We conducted a nested case-control study among Japanese-American men who provided a serum sample and have been followed prospectively for over 20 years to identify 249 incident cases of prostate cancer.

Materials and Methods

Study Population. Between 1965 and 1968, 8006 Japanese-American men were examined by the Honolulu Heart Program on the Hawaiian island of Oahu. They were born between 1900 and 1919 and were approximately 45–68 years of age at the time of examination. Approximately 6 years later, 6860 of these men returned for another round of examination between 1971 and 1975. At that time, a nonfasting venous blood sample was obtained. The sera were stored at −75°C, and serum samples were available on 6811 (99%) of the 6860 men recruited for the study.

The 6860 men were asked to name their brothers at the time of their reexamination. As a result, 3843 additional broth-
Selenium and Prostate Cancer

Table 1: Characteristics of prostate cancer cases and matched controls

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Cases (n = 249)</th>
<th>Controls (n = 249)</th>
<th>Two-sided P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Born in United States (%)</td>
<td>88.4</td>
<td>85.5</td>
<td>0.42</td>
</tr>
<tr>
<td>Buddhist/Shinto religion (%)</td>
<td>67.5</td>
<td>68.7</td>
<td>0.79</td>
</tr>
<tr>
<td>High school education (%)</td>
<td>57.8</td>
<td>49.8</td>
<td>0.07</td>
</tr>
<tr>
<td>Married once (%)</td>
<td>88.3</td>
<td>86.7</td>
<td>0.69</td>
</tr>
<tr>
<td>Alcohol use (%)</td>
<td>76.3</td>
<td>75.1</td>
<td>0.83</td>
</tr>
<tr>
<td>Mean systolic blood pressure (mmHg)</td>
<td>135.7</td>
<td>137.9</td>
<td>0.23</td>
</tr>
<tr>
<td>Mean serum cholesterol (mg/dl)</td>
<td>218.3</td>
<td>217.8</td>
<td>0.92</td>
</tr>
<tr>
<td>Mean body mass index (kg/m²)</td>
<td>23.8</td>
<td>24.0</td>
<td>0.40</td>
</tr>
</tbody>
</table>

*The exact binomial probability test for matched sample was used for comparing proportions; a paired t test was used for comparing means.

ers were identified who were born between 1889 and 1938. Of these, 2553 (66% of the total) were subsequently recruited and examined between 1975 and 1977. A nonfasting venous blood sample was also obtained from 2534 of the examined brothers and stored at −75°C.

The data collected on these men included birthplace, marital status, religion, education, history of alcohol use, cigarette smoking history, blood pressure, and body mass index, based on weight (kg)/height (m²). Serum cholesterol values were determined by the AutoAnalyzer N-24A method. A total of 28 of the 9345 men had been diagnosed with prostate cancer before their examination and were thus excluded from the study.

To identify cases of prostate cancer occurring among the men during the study, discharge records of all general hospitals on Oahu were monitored. To reduce the possibility of missing diagnosed cases, a computer linkage file was established with the Hawaii Tumor Registry, a member of the Surveillance, Epidemiology and End Results Program of the National Cancer Institute. The data should be nearly complete because only 2.5% of the 6860 reexamined men could not be located on Oahu.

There were 360 cases of prostate carcinoma diagnosed between 1972 and 1995 and confirmed by examination of tissue obtained surgically or by biopsy. An additional 26 cases were diagnosed clinically but were not confirmed histologically and were excluded from the study. Because resources were not sufficient to measure serum selenium levels in all 360 cases and their controls, a table of random numbers was used to identify the 249 tissue-confirmed incident cases.

The severity of disease was divided into three categories: (a) occult, in which tumors were found incidental to TURs; (b) localized, defined as clinical tumors confined to the prostate or found incidentally in more than three TUR chips; and (c) advanced, defined as tumors extending beyond the capsule of the prostate. There were 52 occult, 120 localized, and 64 advanced cases identified in this study. The severity of disease could not be determined for three cases.

Each case patient was matched with one control subject from the study. The controls were selected so that the members of each case-control pair were born within 1 year of each other, except for eight pairs (median difference, 1.3 years), and were examined within 1 month of each other, except for 15 pairs (median difference, 1.5 months). They were also matched on whether they were among the 6811 original cohort men or among the 2534 brothers. Each control subject was alive and did not have any cancer diagnosis at the time of the diagnosis of their matched case. Therefore, death was not a competing risk in this study.

The frozen sera were sent in dry ice to Cornell University (Ithaca, NY) for analysis. The laboratory technician could not distinguish sera of cases from those of controls and analyzed them in a random fashion.

Laboratory Analysis. Selenium was determined in serum by automated electrothermal atomic absorption spectrophotometry using pyrolytically coated graphite tubes on an instrument (VARIAN Spectra AA-600; Walnut Creek, CA) equipped with an electrodeless discharge lamp and automatic Zeeman-effect background correction. Samples were mixed with 3 volumes of a matrix modifier solution (1.25% Ni(NO₃)₂.6H₂O, 0.09% PdCl₂, and 0.1% Triton X-100). For each analysis, 20 μl of the serum-matrix modifier solution, followed by 5 μl of a solution of reducing agent (3% hydroxylamine), were delivered to the graphite tube by the autosampler. Absorption was measured at 196.3 nm with a 2.0 nm slit during step 8; signal peak area was calibrated automatically using aqueous solutions of Na₂SeO₃ as standards. The limit of detection of this method is about 25 pg of selenium; using the volumes described above, this yielded a detection limit of about 20 ng selenium/ml serum. Quality control was effected using multiple aliquots of exhaustively analyzed human serum as external control samples, with a coefficient of variation of 7% (for duplicate analyses) being used as the criterion for acceptance of all sample results. That criterion was derived experimentally using the variance components analysis as described previously (20).

Data Analysis. We used the binomial probability test, which is the exact test counterpart of the McNemar test (21), and the paired t test to compare, respectively, the proportion and mean value between cases and their matched controls (Table 1).

Mean body mass index (kg/m²) 23.8 24.0 0.40
Mean systolic blood pressure (mmHg) 135.7 137.9 0.23
Mean serum cholesterol (mg/dl) 218.3 217.8 0.92
Mean body mass index (kg/m²) 23.8 24.0 0.40

Table 2: Age-adjusted ORs* and 95% confidence intervals for prostate cancer by cigarette smoking

<table>
<thead>
<tr>
<th>Cigarette smoking history</th>
<th>No. of cases/controls</th>
<th>ORs</th>
<th>95% CI</th>
<th>Adjusted ORs</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonsmoker</td>
<td>87/98</td>
<td>1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Past smoker</td>
<td>86/83</td>
<td>1.2</td>
<td>0.8–1.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>76/67</td>
<td>1.3</td>
<td>0.8–2.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1–30 pack-years</td>
<td>20/16</td>
<td>1.4</td>
<td>0.7–2.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;30 pack-years</td>
<td>56/51</td>
<td>1.2</td>
<td>0.8–2.0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* ORs and 95% confidence intervals were estimated by the Generalized Estimating Equations approach to correct for intracluster correlation.

Table 3: ORs* for prostate cancer by quartile of serum selenium levels

<table>
<thead>
<tr>
<th>Selenium quartile (ng/ml)</th>
<th>No. of cases/controls</th>
<th>ORs</th>
<th>95% CI</th>
<th>Adjusted ORs</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (&lt;119.3)</td>
<td>75/62</td>
<td>1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 (119.3 &lt; 130.6)</td>
<td>64/63</td>
<td>0.9</td>
<td>0.5–1.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 (130.6 &lt; 147.2)</td>
<td>72/62</td>
<td>0.9</td>
<td>0.6–1.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 (≥147.2)</td>
<td>38/62</td>
<td>0.5</td>
<td>0.3–0.9</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* ORs and 95% confidence intervals (CIs) were estimated by the Generalized Estimating Equations approach to correct for intracluster correlation.

Quartiles were based on the cutpoint value of the controls.

ORs were adjusted for cigarette smoking history (nonsmoker, past smoker, or current smoker) in addition to age by matching.

5 The abbreviations used are: TUR, transurethral resection; OR, odds ratio.
Because serum selenium showed a discernibly skewed distribution, we compared the median serum selenium level between cases and matched controls by the Wilcoxon’s signed rank test.

The risk of prostate cancer associated with cigarette smoking (Table 2) and serum selenium (Tables 3 and 4) was assessed by the OR estimated by the generalized linear model, of which the response variable is binomial, and the link function is logit (22). Because some of the men in our study sample are brothers who are likely to be correlated in the risk for prostate cancer, we used the Generalized Estimating Equations approach, specifying an exchangeable “working” correlation matrix to correct for possible intracluster correlation (23, 24).

The serum selenium values were categorized into quartiles according to the frequency distribution of the matched controls to create a set of binary indicator variables with the lowest category as the reference group. These indicator variables were used as explanatory variables in the generalized linear model. The test for trend was performed using the quartile frequency class midpoints as an explanatory variable, and the score statistic was used to assess the two-sided statistical significance.

### Results

The mean age of the 249 prostate cancer cases and their matched controls at time of their examination was 61.2 years, and their ages ranged from 44.0–85.1 years. The average interval from exam to diagnosis was 12.4 years for the cancer patients. The average age at time of diagnosis was 73.6 years for the cases.

A comparison of cases and controls by their demographic characteristics and laboratory values is presented in Table 1. The two groups were similar in birthplace, religion, marital status, alcohol use, blood pressure, serum cholesterol, and body mass index. More cases than controls had a high school education, but the difference was not statistically significant.

Table 2 shows the relation of cigarette smoking to prostate cancer risk in this study population. Both past and current smokers had a higher risk compared with nonsmokers, but the association was not statistically significant. There was also no dose-response relationship for current smokers.

The serum selenium values ranged from 72.8–205.0 ng/ml in the prostate cancer cases and from 77.1–227.7 ng/ml in their controls. The median serum selenium value was 128.0 ng/ml in cases and 131.6 ng/ml in the controls, which was not statistically significant (two-sided test, based on log-transformed serum selenium data).

In Table 4, the cases were separated according to age at diagnosis, time interval since examination, severity of disease, and cigarette smoking history. The 19 cases who were diagnosed within 5 years of their examination were not included in the time interval analysis to lessen the effect of undiagnosed prostate cancer at time of phlebotomy. The median serum selenium value was 125.1 ng/ml in cases and 132.9 ng/ml in the controls, which was not statistically significant.

### Table 4 ORs for prostate cancer by serum selenium levels, stratified by age at diagnosis, time interval between examination and diagnosis, severity of disease, and cigarette smoking history

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No. of cases</th>
<th>Quartile 2 OR (95% CI)</th>
<th>Quartile 3 OR (95% CI)</th>
<th>Quartile 4 OR (95% CI)</th>
<th>Two-sided P for trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis’</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤75 years</td>
<td>151</td>
<td>0.8 (0.4–1.8)</td>
<td>1.1 (0.5–2.6)</td>
<td>0.7 (0.3–1.6)</td>
<td>0.19</td>
</tr>
<tr>
<td>&gt;75 years</td>
<td>98</td>
<td>1.0 (0.5–2.2)</td>
<td>0.8 (0.4–1.7)</td>
<td>0.8 (0.3–1.8)</td>
<td>0.48</td>
</tr>
<tr>
<td>Interval since exam’</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5–15 years</td>
<td>142</td>
<td>0.9 (0.5–1.8)</td>
<td>1.0 (0.5–1.8)</td>
<td>0.4 (0.2–0.9)</td>
<td>0.03</td>
</tr>
<tr>
<td>&gt;15 years</td>
<td>88</td>
<td>0.8 (0.4–1.9)</td>
<td>1.1 (0.5–2.7)</td>
<td>0.7 (0.3–1.6)</td>
<td>0.52</td>
</tr>
<tr>
<td>Severity of disease’</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Occult</td>
<td>62</td>
<td>0.4 (0.1–1.1)</td>
<td>0.5 (0.2–1.4)</td>
<td>0.4 (0.1–1.2)</td>
<td>0.19</td>
</tr>
<tr>
<td>Localized</td>
<td>120</td>
<td>1.1 (0.5–2.2)</td>
<td>1.2 (0.6–2.4)</td>
<td>0.8 (0.4–1.8)</td>
<td>0.76</td>
</tr>
<tr>
<td>Advanced</td>
<td>64</td>
<td>1.0 (0.4–2.8)</td>
<td>0.9 (0.4–2.5)</td>
<td>0.3 (0.1–0.8)</td>
<td>0.01</td>
</tr>
<tr>
<td>Smoking history’</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonsmoker</td>
<td>87</td>
<td>0.6 (0.3–1.5)</td>
<td>1.3 (0.6–3.0)</td>
<td>0.8 (0.4–1.9)</td>
<td>0.93</td>
</tr>
<tr>
<td>Past smoker</td>
<td>86</td>
<td>1.3 (0.5–3.2)</td>
<td>0.7 (0.3–1.6)</td>
<td>0.5 (0.2–1.1)</td>
<td>0.03</td>
</tr>
<tr>
<td>Current smoker</td>
<td>76</td>
<td>0.9 (0.4–2.1)</td>
<td>0.9 (0.4–2.1)</td>
<td>0.2 (0.1–0.8)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

a ORs and 95% confidence intervals (CIs) were estimated by the Generalized Estimating Equations approach to correct for intrACLuster correlation.

b Quartiles were based on the cutpoint value of the controls. Quartile 1 (lowest) was used as the reference group.

c Adjusted for age because the age-matched case-control pairs were not retained in the subgroups.

d Adjusted for age because the age-matched case-control pairs were not retained in the subgroups.

### Discussion

Japanese men living in Hawaii have an average prostate cancer incidence rate of 64.2 per 100,000 per year, which is clearly lower than the rate of 108.2 among Caucasian men in Hawaii (25). However, Japanese men living in Hawaii have a prostate cancer risk that is significantly higher than that of Japanese men living in Hiroshima, Japan, who have an average incidence rate of 10.9 per 100,000 per year. These data provide support that
environmental factors have influenced the difference in rates between Japanese men in Hawaii and Hiroshima.

Serum selenium was inversely related to the risk of prostate cancer in our study population. The association was strongest for the 64 patients whose tumor extended beyond the prostate gland, supporting the clinical relevance of the association. Among the 62 occult cancer cases, there was also an inverse association, but it was not statistically significant. These cases were usually diagnosed incidentally after a TUR for benign prostatic hypertrophy.

To minimize the possible effects of undiagnosed prostate cancer lowering the selenium levels, patients diagnosed within the first 5 years of follow-up were excluded. The inverse association persisted, especially in patients who were diagnosed 5–15 years after recruitment into the study. Because the cases and controls came from the same identified population, this investigation found no association among residents in Finland, and the largest study included 249 cases and controls, but they were not statistically significant (18, 19). A serum selenium levels in prostate cancer cases compared with smaller studies, conducted in the United States, reported lower levels that would suggest suboptimal expression of glutathione peroxidase activity; only two cases had serum selenium concentrations that would suggest suboptimal expression of glutathione peroxidase activity or related antioxidant enzymes. Furthermore, the threshold above which there is maximal expression of selenoenzymes and thioredoxin reductase) makes it inviting to consider this function as the basis of a linkage between selenium status and cigarette smoking because the latter is known as a source of oxidative stress (37, 38). However, few, if any, of the subjects in the present study had serum selenium levels that would suggest suboptimal expression of glutathione peroxidase activity; only two cases had serum selenium concentrations less than 85 ng/mL, which Neve (39) has shown to be the threshold above which there is maximal expression of selenoenzyme. Because greater selenium levels are not expected to increase the expression of selenoenzymes, it must be considered unlikely that the suggested protective effect associated with the relatively high selenium levels in this population relates to differences in antioxidant enzymes. Furthermore, the lack of a strongly positive association between smoking and prostate cancer risk in our data dictates that caution be exercised in interpreting the results. Additional studies are needed to determine whether there is an inverse association between serum selenium and prostate cancer, and whether this association is present mainly in cigarette smokers.

Acknowledgments

We are grateful to Mary Brindak for her assistance in the laboratory. We are indebted to the Honolulu Heart Program for the use of its data and to the following institutions for their helpful cooperation: Castle Medical Center, Kaiser Medical Center, Kapiolani Medical Center at Pali Momi, Queen’s Medical Center, St. Francis Medical Center, St. Francis-West Hospital, Straub Clinic and Hospital, Tripler Army Medical Center, Wahiawa General Hospital, and the Hawaii Tumor Registry, all of which are located on Oahu, Hawaii.
References


Serum Selenium and Subsequent Risk of Prostate Cancer

Abraham M. Y. Nomura, James Lee, Grant N. Stemmermann, et al.


Updated version
Access the most recent version of this article at:
http://cebp.aacrjournals.org/content/9/9/883

Cited articles
This article cites 31 articles, 9 of which you can access for free at:
http://cebp.aacrjournals.org/content/9/9/883.full#ref-list-1

Citing articles
This article has been cited by 24 HighWire-hosted articles. Access the articles at:
http://cebp.aacrjournals.org/content/9/9/883.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.